Flatiron Health

While the industry has long been limited to describing 'what is' happening in cancer care, Flatiron Health pioneering the next evolution—uncovering the 'why' behind clinical decisions and predicting the 'what will be' of patient outcomes. Today, we're announcing breakthrough scientific innovations that fundamentally transform cancer research capabilities: 🔬 LLM-extracted real-world progression at unprecedented scale 📊 The industry's first comprehensive approach to evaluating AI-extracted data quality, benchmarked against expert human abstraction 🌍 Harmonized multinational real-world datasets that break down borders to enable truly global cancer research These aren't incremental improvements—they're foundational innovations that redefine what's possible in cancer research. With more than 5 million patient records and 1.5 billion data points available for research, we're building toward a future where research shifts from reactive analysis to proactive insight generation. Learn more: https://lnkd.in/eFfNfnWe

How can AI responsibly change whats possible for cancer research? Aaron Cohen, MD, MSCE, Head of Clinical Data at Flatiron Health, joined the ThinkData Podcast to explore the promise — and the guardrails — of using real-world data and machine learning in oncology. Tune in for a thoughtful conversation on data quality, fairness, and the future of AI in life sciences. https://lnkd.in/gWE_tFTh

Featured research at ESMO 2025 ⬇️ We're presenting two compelling studies alongside our research partners in Berlin: CDK4/6 inhibitor treatment patterns in mBC—Understanding how these therapies are being utilized in real-world clinical practice, providing insights that complement clinical trial data. NTRK+ solid tumor outcomes—Uncovering outcome patterns from comprehensive real-world data that inform treatment decisions and improve patient care. Visit us at #ESMO2025 to learn how Flatiron's real-world evidence solutions are accelerating research and advancing patient care worldwide. https://lnkd.in/euQwxscr

Looking for a role where your day-to-day work drives real-world impact? At Flatiron Health, our teams are improving lives by turning data into powerful insights for cancer care and research. Explore open roles and discover how your career can create change: https://bit.ly/3ONI8pC

Innovation in #realworldevidence demands not just powerful tools, but rigorous validation. Read our recent article by Melissa Estevez, Director of Research Sciences, to learn more about the use of #LLMs to extract data from unstructured EHR text and the VALID Framework, our three-pillar approach to ensure that automatically extracted datasets are not only accurate at the variable level, but also consistent, representative, and fit for the studies they’re used for. Key takeaways: even small errors can create cascading issues; high variable-level accuracy doesn’t always guarantee usability in downstream analyses; and asking the right validation questions is essential. If you rely on real-world data—whether for oncology research, outcomes analysis, drug development, or beyond—this article provides tools and perspectives to help you assess whether your data “passes the VALID test.” Read more and learn what rigorous data validation should look like: https://lnkd.in/eFmvf5fR

At #ESMO2025, discover Flatiron's comprehensive approach to evidence generation: #RWD | Our longitudinal, patient-level data spans diverse treatment settings and patient populations, providing insights and enabling broader patient analyses. Evidence Services | Your expert partner to generate actionable insights and evidence that advance your oncology portfolio and inform critical decisions. Regulatory-grade #RWE | Tailored to your research objectives with the highest standards for supporting research, regulatory submissions, and clinical decision-making. The future of oncology research is built on comprehensive, high-quality real-world evidence. See you in Berlin. https://lnkd.in/euQwxscr

In Flatiron Health's most recent article, Rezwan Badhan; Director of Pharmacovigilance, explores how the evolution of digital health technologies offers more efficient ways to generate safety evidence in the post-marketing setting. Curious how innovation is shaping the future of oncology research? Read more: https://lnkd.in/e9DiCbEH

#ctDNA is emerging as a powerful tool in oncology, with #RWE helping us understand how it’s being adopted and what it means for patient care. At Flatiron, we’re studying not just the promise of ctDNA, but also its real clinical impact—from recurrence monitoring to therapy decision-making. In a new article, Erin Fidyk, MSN, MBA, Senior Clinical Director at Flatiron Health, explores the evolving role of “tumor-informed” ctDNA testing and what it means for both researchers and clinicians. Real-world evidence offers a unique lens: helping uncover how these tests are used outside of trials, where they drive the most value, and how molecular signals connect to outcomes at scale. 🎥 Watch the video overview and read the full article: spkl.io/6011ApGec

We're heading to #ESMO2025 in Berlin to showcase how we’re delivering oncology evidence across global markets. Join us to explore breakthrough research and innovative solutions: • New insights on CDK4/6 inhibitor treatment patterns in breast cancer • Compelling findings on NTRK+ solid tumor outcomes • Evidence services that accelerate time to insights Learn more about our presence and RSVP for our networking reception ⬇️ https://lnkd.in/grisC_a3

At Flatiron Health, we believe that innovation in #realworldevidence demands not just powerful tools, but rigorous validation. Our latest article, by Melissa Estevez, Director of Research Sciences, dives into the use of #largelanguagemodels to extract data from unstructured EHR text—and introduces the VALID Framework, our three-pillar approach to ensure accuracy, consistency, and fit-for-purpose data. We explore how even small alignment issues (like date mis-assignments or shifts in variable performance across subgroups) can impact downstream research, why human oversight is still essential, and what questions clients should ask of any RWD provider. If you rely on real-world data—whether for oncology research, outcomes analysis, drug development, or beyond—this article provides tools and perspectives to help you assess whether your data “passes the VALID test.” Read more and learn what rigorous data validation should look like: https://lnkd.in/eFmvf5fR